Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1991 2
1992 1
1993 1
1994 5
1995 7
1996 5
1997 10
1998 6
1999 7
2000 6
2001 8
2002 3
2003 3
2004 9
2005 15
2006 8
2007 9
2008 8
2009 14
2010 12
2011 4
2012 13
2013 18
2014 21
2015 23
2016 27
2017 17
2018 29
2019 34
2020 52
2021 49
2022 57
2023 24

Text availability

Article attribute

Article type

Publication date

Search Results

440 results

Results by year

Filters applied: . Clear all
Page 1
NAFLD: a multisystem disease.
Byrne CD, Targher G. Byrne CD, et al. J Hepatol. 2015 Apr;62(1 Suppl):S47-64. doi: 10.1016/j.jhep.2014.12.012. J Hepatol. 2015. PMID: 25920090 Free article. Review.
Nonalcoholic Fatty Liver Disease in Children.
Mann JP, Valenti L, Scorletti E, Byrne CD, Nobili V. Mann JP, et al. Among authors: byrne cd. Semin Liver Dis. 2018 Feb;38(1):1-13. doi: 10.1055/s-0038-1627456. Epub 2018 Feb 22. Semin Liver Dis. 2018. PMID: 29471561 Free article. Review.
Non-alcoholic fatty liver disease and childhood obesity.
Shaunak M, Byrne CD, Davis N, Afolabi P, Faust SN, Davies JH. Shaunak M, et al. Among authors: byrne cd. Arch Dis Child. 2021 Jan;106(1):3-8. doi: 10.1136/archdischild-2019-318063. Epub 2020 May 14. Arch Dis Child. 2021. PMID: 32409495 Review.
MAFLD and risk of CKD.
Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, Targher G, Byrne CD, Yuan WJ, Zheng MH. Sun DQ, et al. Among authors: byrne cd. Metabolism. 2021 Feb;115:154433. doi: 10.1016/j.metabol.2020.154433. Epub 2020 Nov 16. Metabolism. 2021. PMID: 33212070
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review.
Mantovani A, Byrne CD, Targher G. Mantovani A, et al. Among authors: byrne cd. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):367-378. doi: 10.1016/S2468-1253(21)00261-2. Epub 2022 Jan 12. Lancet Gastroenterol Hepatol. 2022. PMID: 35030323 Review.
440 results